drugset / Trial / NCT01323985
SAP Depleter Dose Escalation Study in Healthy Volunteers
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to provide safety information and to define the optimal induction and short term maintenance regimen for GSK2315698 to deplete circulating SAP in healthy volunteers prior to assessing in patients
Timeline
- Start
- 2011-01-06
- Primary completion
- 2011-06-30
- Completion
- 2011-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | miridesap | Small molecule | 5 mg | Intravenous |
| Subject | miridesap | Small molecule | 400 mg | Intravenous |